Х Айвазян, З ИкрамовР., Ю Степанова, Б ВараваА., Минздрава России, Большая Серпуховская, Российская Федерация, Сеченова Минздрава России, Большая Сухаревская пл, A. VishnevskyV., Stepanova Yu, Kovalenko Yu, Zharikov Yu, Pakhomova A. Yu
{"title":"肝细胞癌治疗的现代原则","authors":"Х Айвазян, З ИкрамовР., Ю Степанова, Б ВараваА., Минздрава России, Большая Серпуховская, Российская Федерация, Сеченова Минздрава России, Большая Сухаревская пл, A. VishnevskyV., Stepanova Yu, Kovalenko Yu, Zharikov Yu, Pakhomova A. Yu","doi":"10.16931/1995-5464.2020215-26","DOIUrl":null,"url":null,"abstract":"Aim. To improve the treatment outcomes, quality and life expectancy, prognosis in patients with hepatocellular carcinoma based on an analysis of treatment outcomes.Materials and methods. The analysis of the long-term results of treatment of 114 patients with hepatocellular carcinoma for 2015–2020 was carried out. Two groups of patients were distinguished: 41 (35.9%) patients were included in group I (a potentially resectable tumor with R0 surgery), and 63 (55.2%) patients were included in group II (advanced tumor does not suggest R0 resection).Results. Actuarial survival for patients with R0 surgery (48) was: 1 year – 85%, 3 years – 65%, 5 years – 55%; in patients with unresectable tumor after transarterial chemoembolization: 1 year – 65%, 3 years – 29%, 5 years – 11%; after local destruction methods – 0.5 years – 75%, 1 year – 36%, 1.5 years – 22%.Conclusions. The results of treatment of patients with hepatocellular carcinoma confirm the feasibility and effectiveness of a rational multidisciplinary approach. It allows you to achieve satisfactory results in multidisciplinary hospitals. The results are consistent with the data of large surgical centers.","PeriodicalId":505469,"journal":{"name":"Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery","volume":"52 19","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Modern principles of hepatocellular carcinoma treatment\",\"authors\":\"Х Айвазян, З ИкрамовР., Ю Степанова, Б ВараваА., Минздрава России, Большая Серпуховская, Российская Федерация, Сеченова Минздрава России, Большая Сухаревская пл, A. VishnevskyV., Stepanova Yu, Kovalenko Yu, Zharikov Yu, Pakhomova A. Yu\",\"doi\":\"10.16931/1995-5464.2020215-26\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim. To improve the treatment outcomes, quality and life expectancy, prognosis in patients with hepatocellular carcinoma based on an analysis of treatment outcomes.Materials and methods. The analysis of the long-term results of treatment of 114 patients with hepatocellular carcinoma for 2015–2020 was carried out. Two groups of patients were distinguished: 41 (35.9%) patients were included in group I (a potentially resectable tumor with R0 surgery), and 63 (55.2%) patients were included in group II (advanced tumor does not suggest R0 resection).Results. Actuarial survival for patients with R0 surgery (48) was: 1 year – 85%, 3 years – 65%, 5 years – 55%; in patients with unresectable tumor after transarterial chemoembolization: 1 year – 65%, 3 years – 29%, 5 years – 11%; after local destruction methods – 0.5 years – 75%, 1 year – 36%, 1.5 years – 22%.Conclusions. The results of treatment of patients with hepatocellular carcinoma confirm the feasibility and effectiveness of a rational multidisciplinary approach. It allows you to achieve satisfactory results in multidisciplinary hospitals. The results are consistent with the data of large surgical centers.\",\"PeriodicalId\":505469,\"journal\":{\"name\":\"Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery\",\"volume\":\"52 19\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-06-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.16931/1995-5464.2020215-26\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.16931/1995-5464.2020215-26","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Modern principles of hepatocellular carcinoma treatment
Aim. To improve the treatment outcomes, quality and life expectancy, prognosis in patients with hepatocellular carcinoma based on an analysis of treatment outcomes.Materials and methods. The analysis of the long-term results of treatment of 114 patients with hepatocellular carcinoma for 2015–2020 was carried out. Two groups of patients were distinguished: 41 (35.9%) patients were included in group I (a potentially resectable tumor with R0 surgery), and 63 (55.2%) patients were included in group II (advanced tumor does not suggest R0 resection).Results. Actuarial survival for patients with R0 surgery (48) was: 1 year – 85%, 3 years – 65%, 5 years – 55%; in patients with unresectable tumor after transarterial chemoembolization: 1 year – 65%, 3 years – 29%, 5 years – 11%; after local destruction methods – 0.5 years – 75%, 1 year – 36%, 1.5 years – 22%.Conclusions. The results of treatment of patients with hepatocellular carcinoma confirm the feasibility and effectiveness of a rational multidisciplinary approach. It allows you to achieve satisfactory results in multidisciplinary hospitals. The results are consistent with the data of large surgical centers.